
|Videos|July 1, 2021
Efficacy of Dapagliflozin in the Treatment of Patients With Type 2 diabetes Hospitalized With COVID-19
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained what some of the findings were around the efficacy of dapagliflozin in patients during the DARE-19 trial.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Building the pharmacy of the future — trust, loyalty, and growth
2
Oral GLP-1s Expand Obesity Treatment Options in 2026
3
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
4
Understanding Axatilimab's Mechanism in the Context of Multiple Lines of Therapy
5


































































































